On Friday, Leerink Partners adjusted their financial outlook for Lexicon Pharmaceuticals (NASDAQ: NASDAQ:LXRX), increasing the price target to $6.00 from the previous $5.00 while maintaining an Outperform rating. The revision comes in response to Lexicon's recent licensing agreement with Viatris for the drug sotagliflozin in markets outside of the United States and Europe.
The analyst at Leerink Partners sees the agreement as a strong strategic move for Lexicon, which could reinforce the company's position in the cardiometabolic space. The deal with Viatris is expected to provide Lexicon with royalties and milestones that can be reinvested into the company's portfolio. It also clarifies Lexicon's approach to global commercialization and is anticipated to enhance their long-term revenue prospects.
Lexicon's pipeline programs are currently considered undervalued by investors, according to Leerink Partners. These programs target various conditions with high unmet medical needs, including Type 1 diabetes with chronic kidney disease, hypertrophic cardiomyopathy, diabetic peripheral neuropathic pain, and obesity.
The firm identified upcoming events that could influence Lexicon's stock. These include potential sales inflection of Inpefa for heart failure into 2025 and the outcome of the FDA advisory committee meeting for Zynquista on October 31, 2024. A positive result could signal a favorable outlook for Zynquista's potential approval in the United States for Type 1 diabetes with chronic kidney disease by the PDUFA date of December 20, 2024.
Leerink Partners has updated their financial model to incorporate the terms of the deal with Viatris, which led to the rise in the price target for Lexicon Pharmaceuticals to $6.00. The firm reiterates its Outperform rating on the stock.
In other recent news, Lexicon Pharmaceuticals secured an exclusive licensing agreement with Viatris for the commercialization of the diabetes drug sotagliflozin outside of the United States and Europe. This strategic partnership is set to extend the global reach of sotagliflozin, with Lexicon receiving a $25 million upfront payment from Viatris, and potential for additional milestone payments. Analyst firms Piper Sandler and H.C. Wainwright have maintained positive ratings for Lexicon, underscoring the potential of the company's drugs.
Lexicon reported a net loss of $53.4 million in Q2 2024, with revenues of $1.6 million, primarily from sales of INPEFA, the marketed form of sotagliflozin. The company is also preparing for an FDA review of Zynquista and has initiated patient enrollment for the Phase 3 SONATA trial of sotagliflozin in hypertrophic cardiomyopathy.
In executive changes, Jeffrey L. Wade has ended his tenure as president and COO, with Kristen L. Alexander stepping into the role of principal financial officer. Lexicon also anticipates top-line data for the LX9211 study in diabetic peripheral neuropathic pain by Q2 2025.
InvestingPro Insights
Recent data from InvestingPro adds context to Leerink Partners' optimistic outlook on Lexicon Pharmaceuticals. The company's market capitalization stands at $726.6 million, reflecting investor interest in its potential. InvestingPro Tips highlight that Lexicon holds more cash than debt on its balance sheet and has liquid assets exceeding short-term obligations, which could provide financial flexibility as it pursues its strategic initiatives and pipeline development.
The company's revenue growth is particularly noteworthy, with InvestingPro data showing a staggering 794.59% increase in the last twelve months as of Q2 2024. This aligns with the InvestingPro Tip indicating that analysts anticipate sales growth in the current year, supporting Leerink's positive view on Lexicon's revenue prospects.
However, investors should note that Lexicon is currently not profitable, with a negative gross profit margin and operating income. An InvestingPro Tip cautions that the company is quickly burning through cash, which may be a consideration for long-term investment strategies.
For those interested in a more comprehensive analysis, InvestingPro offers 12 additional tips for Lexicon Pharmaceuticals, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.